• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

10.01.2025
Dollar Strength Is a Given

The very first slice of statistical data on business activity from the United States this year reaffirmed an almost clear irrelevance and even potential hurtfulness of any immediate steps towards further lowering interest rates on U.S. Dollar-nominated loans from a purely economic point of view. The ISM Manufacturing PMI (Purchasing Managers Index), based on polls compiled from executives in over 400 industrial companies in late December, came out at 49.3 points vs 48.4 a month ago and 48.2 in average analyst estimates. This showed that a slowdown was occurring at a slower or even insignificant pace, keeping inflation risks on the table, especially when the price component increased from 50.3 to 52.5 with a similar rate of increase in new orders. Meanwhile, non-manufacturing PMI came out at 54.1 on Tuesday, compared to 53.5 in analyst polls and 52.1 a month ago, with a contribution of business activity components even jumped to a surprising 58.2 against declining from 57.2 in November to only 53.7 in December.

In other words, the economy is not cooling, and is rather in a positive acceleration, which in turn may lead to a recovery in wage rises and therefore to higher demand pressure, which may be reflected soon in higher producer purchase and output prices. Doubts of the major U.S. financial regulator are understandable at this point after its triple rate cut from 5.5% to 4.5% in 2024. The Federal Reserve (Fed) will now pay closer attention not only to consumer inflation measures, but also to producer prices (PPI), which is just going to be released on coming Tuesday, January 14. And so, this will become the next reference point in the further U.S. Dollar’s trajectory. The Greenback index (DX) is picking up steam since reaching a new record high for the last two years at 109.35, with its temporary pullbacks being limited by a 107.50 support area that previously served as a strong multi-month technical resistance.

In this context, the British Pound (GBPUSD) updated its lows since November 2023 to touch 1.2237 on January 9, EURUSD feels quite comfortable within a range between 1.02 and 1.0450, which corresponds to its 2-year bottom, and having a bias towards a possible further decline. The Aussie (AUDUSD) is one-step away from taking the path for a breakthrough to a quite unknown territory of its 5-year lows that were last time recorded when the initial outbreak of the Covid-19 happened.

A varying extent of the American Dollar strength is surely data dependent as the market community is eagerly waiting for the U.S. job data later today. The average expectations on new Nonfarm Payrolls is just a bit above 150,000 vs 227,000 in early December 2024 and nearly 160,000 for the previous four months on average. However, any value close to 150,000, plus or minus 20,000, or any higher number, may be considered as another positive sign for the Greenback, following the ADP national employment report which contained only 122,000 on Wednesday. The oppressive nature of average hourly wage in its dynamics, +0.4% each time from September to December, also matters.

The protective quality of investing more funds into the U.S. Dollar and U.S. bonds against tariff threats is switched on anyway, based on more than a 95% chance for the Fed to keep rates on pause at its January 29 meeting, according to CME's FedWatch tool. Federal Reserve officials never go against a well-established market consensus, when it is almost unanimous, for not to rock the boat of relative market trend stability. The central bankers' reluctance to shift the Fed fund rates lower before mid-March, if not early May, continues to play in favour of short-term speculative transactions on the foreign exchange market, bearing in mind all the listed currency instruments. Some intraday volatility may take place, especially in the case of appearing an abnormal two-digit non-farm value, but not a change in overall direction.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

06.02.2025
Perfect As the Enemy of Good

Here is the problem, which is nearly at a primary school level. A simple logical puzzle. A shopping street has two grocery stores. One of the stores is much more popular than the other. But both shops are full of customers every day. So both shops are raking in money. Sales output of a more popular store roughly doubled over the past year, from $14.5 billion to $30.8 billion - oh, yes, it's a very big shop - which led to tripling of its market value. Meanwhile, sales in the second store have already grown by 69%, albeit by its lower standards, namely from $2.3 billion to $3.9 billion. Please draw a conclusion, by what percentage the market value of the second store could increase, assuming that professional appraisers are rather objective. It seems ridiculous, but the correct answer is that the second store's market value lost 35% within the same year, and it even dropped by 50% from its peak price of the last spring. Holy Cow! That was a story of some failed expectations of mine. Since the big store is, of course, Nvidia, and the small one (and also, in fact, quite a prosperous marketplace) is Advanced Micro Devices (AMD). And their goods are not essential food, but chips for artificial intelligence (AI) related data centers, which are also in high demand.

Moreover, AMD shares reportedly tumbled 10% additionally on February 5, only because the firm's AI chip revenue failed to be exactly in line with elevated projections of Wall Street analyst pool, which somehow bet on a 80% pace of data centre growth to as much as $4.15 billion YoY. Okay, one might say that Nvidia's "store" sells 8 times more chips that everyone needs. And even remember that Nvidia chips are of better quality, that Nvidia occupies about 80% of global chip market share. Again, Nvidia's last quarter will be finally counted only by February 26, when Nvidia's financial report is scheduled, a month later than in AMD's case. Like most large investment houses, here I have provided growth metrics regarding the major data center segment, which is a proxy for the AI playground, where AMD struggles to compete with Nvidia. Well, AMD CEO Lisa Su admitted that her company's data center sales in the current quarter may go down about 7% from the just-ended quarter, but this announcement was exactly in line with an overall expected decline. Is it really such a big deal that AMD shareholders have to experience pain from seeing their chosen stock falling to a 14-month low, with further need for a 100% rally just to match last year's record prices?

The same Lisa Su declined to give the particular forecast for the company's AI chips, but she said that AMD expects "tens of billions" of dollars in sales "in the next couple of years". And I see no reason to doubt her words. AMD CEO added that the firm is now working to compete against Broadcom (AVGO) in collaborating with its customers like Meta and Microsoft to create custom AI chips for their purposes, as Broadcom helps its partners to design their own chips, contrary to mostly "off-the-shelf" processors by AMD and Nvidia. They know their weaknesses as opportunities for strengthening to work in that direction, so what's wrong with the market's adequacy of perception? Perfect Nvidia is the enemy of good AMD, according to the crowd's opinion. Besides AI chips, AMD is also one of the largest providers of personal computer chips. Until recently, this point was generally the source of their main income. Consumers continue to buy new PCs, which also can handle generative AI tasks, by the way.

Actually, AMD has been the only loss-making company in my large portfolio for a long time, so it even makes me smile now. At least, because it is only a matter of time before AMD's pogo stick ultimately uncoils to come loose. Record annual revenue and earnings have to entail recovering to record market value eventually. I am not sure this will happen in the first half of 2025, even though AMD forecasts its revenue rise between $6.8 billion and $7.4 billion for the current quarter, with the market consensus midpoint being slightly lower at $7.04 billion. If you don't believe me then analysts at Stifel are of the opinion that AMD is well positioned for AI compute and "It is likely" that some of its customers "are waiting for 325/350 systems, which should drive a much stronger second half". Again, the median estimate by the Wall Street's analyst pool was now declined to about $150 per share vs $166.5 before the last downside move, yet even $150 sounds much better compared to $112 on closing price this Wednesday or an intraday low at $106.56 during the last trading session. Anyway, there is a strong technical and psychological support zone near the round figure of $100, from where AMD stock had begun its cool ascension in late 2023.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

Perspective ETFs in the ESG energy segment: Invesco Global Clean Energy Portfolio ETF

This ETF invests in green energy ventures. The pandemic led to a 300% increase of its share price. But since the beginning of 2022 they have lost 30%, twice as much as the S&P 500 SPY ETF. The net capital which has outflown from the Fund has reached $31.5 billion over the last 12 months, while the major outflow was recorded in December 2021. However, its shares are still seen to be overbought as P/E multiplier is at 24 that is well above the average of 20 for the EFT’s that are linked to the S&P 500, while the dividend yields are above PBD’s numbers.

Inflation in the United States is rising negatively affecting all shares with a high P/E ratio. So, we may expect a further decline of the PBD share price and other similar assets that cannot be protected from rising risks. Traditional energies are looking more attractive on this background and could be a perfect hedge asset amidst geopolitical uncertainties. 

4147
Three Stocks that Could Draw Bullish Attention: The Bank of America

Shares of The Bank of America (BAC) scrambled above the $40 technical resistance level in late April. However, the price gained more than 6.5% in the first three trading sessions since the publication of the Q1 2022 financial report of the bank, which turned out to be perhaps the best among all the largest U.S. banking institutions that have already reported. This may be especially valuable due to the fact that the banking sector as a whole has been consistently declining since February due to ongoing concerns of the investment community about the steadiness of loan portfolios in the face of a potential threat of stagflation, which is increasingly being mentioned by various economists. 

A pick-up in lending activities, as well as beating market expectation on both the top and bottom line, including 80 cents of equity per share vs the average Wall Street estimates of just 75 cents and the best-ever result in first quarter revenues of $23.23 billion, helped to attract some dip buying as the Bank of America was trading with an almost 25% discount against the highest price of the beginning of the year. The BAC’s CEO Brian Moynihan encouraged investors with his prediction of a "significant NII [net interest income] improvement through the next several quarters". He also told CNBC’s Jim Cramer on "Mad Money" that spending is healthy despite roaring inflation. U.S. consumers "are a very strong force" and "their loan balances are down, they have plenty of borrowing capacity and they have plenty of spending capacity... In the month of March ’22 versus March ’21, the consumers … spent about 13% more than they did last year, but importantly, in the first couple weeks in April, that numbers moved back to 18%, indicating faster spending in consumers", he added. 

The Federal Reserve’s (Fed) plans of rising interest rates fuel expectations of higher banking income when loan rates will also rise for consumers and businesses, but the ultimate consequences of this process are not yet clear due to possible side effects on the economy and therefore on the loan portfolio's stability. Different stocks of the banking sector also have a good chance to resume their bullish trend at some moment thanks to the rising yield of U.S. Treasury bonds, which is now close to 3% for the benchmark 10-year public debt securities. This may increase the total income from bank reserves invested in such assets. However, a wide understanding that yields are still far away from their maximum values and will soon grow much stronger following inflation, gives the demand a strange form of rather postponed or protracted demand, so the market is still very selective in relation to bank stocks and tends to choose the best options.

2028
Three Stocks that Could Draw Bullish Attention: Johnson & Johnson

The story of the recent market moves for Johnson & Johnson (J&J) is very similar to that of Procter & Gamble, as are the fundamental drivers behind the growth. The outer difference of the technical character is that the price of J&J has already managed to rewrite its historical highs above $185 per share. J&J's capitalisation growth since January 2021 is about the same at 17.5%. The big difference is that the turnaround of J&J's consumer health care production, which include trademarks like Aveeno, Clean & Clear, Carefree, Dabao, Johnson’s Adult and Johnson’s Baby, Le Petite Marseillais, Listerine, Lubriderm etc, was about $14.6 billion in 2021 while the pharmaceutical branch of the company's sales, including drugs for many different diseases, such as pulmonary hypertension, prostate cancer, attention deficit/hyperactivity disorder (ADHD) and psoriasis, made $52 billion. 

The company creates about 0.8% of the world's entire healthcare products, and still has a lot of space to expand. From the geographical point of view, its U.S. related first quarter numbers increased 2.8% while overseas global revenue added 13%. The pharmaceutical branch generated a sales increase of 9.3% while the MedTech segment gave 8.6%. J&J CEOs provided a solid full year’s outlook even after its equity per share of $2.67 showed its best-ever result since the company's foundation in 1886, also mentioning that 2022 should be the 11th consecutive year that the pharmaceuticals business has grown faster than the global market. 

J&J still has an anti-COVID vaccine department, which is currently in a most uncertain stance because of both the demand's structural changes and the excessive supply of other shots, like Pfizer and Moderna. Therefore, J&J which previously tried to forecast its sales at $3.5 billion of its single-dose vaccine, now says it can no longer predict the particular income size. The J&J vaccine, which sold at the so-called "not-for-profit" price, provided the company with $457 million of its revenue in the Q3 2022, much less than its peers did. Pfizer’s sales forecast for 2022 is $32 billion of its COVID vaccine developed with BioNTech, while Moderna gave a $21 billion forecast. "The slight miss was really around the COVID-19 vaccine and quite frankly it met our internal expectations. There was just a disconnect in how the Street assumed it was going to play out over the year," Chief Financial Officer Joseph Wolk remarked during a conference call on April 19. Anyway, this is not a key component of J&J’s activities in the financial terms.

3394
Three Stocks that Could Draw Bullish Attention: Procter & Gamble

The latest financial report from the well-known multinational leader in the consumer goods segment on April 20 showed all signs of the company's stable income. Revenue of $19.38 billion exceeded Wall Street's average expectations of expert pools by 3.5%, and it was also about 7% higher compared to the corresponding seasonal period of 2021, although certainly well below pre-Christmas record figures. Contrary to popular concerns that a heavy pressure of incoming costs is reducing the direct benefit of any manufacturer, earnings per share of $1.33 turned out to be 7 cents higher than a year ago. Distribution of health care items, like Oral-B and Pepto-Bismol, soared by 13%. 

Procter & Gamble (P&G) raised its full-year sales forecast confirming that sales for cleaning products and personal healthcare are resilient despite rising prices. For the fiscal year 2022, the company expects "organic revenue growth in the range of 6% to 7%" to beat the preliminary Reuters poll consensus of just 5.5%. P&G price rose by 3% immediately within the first hour after the opening bell on the day of the release and stopped only at 88 cents lower than the previous all-time peak of January 2022. Yet, it clearly will not rest on this height after adding 17.5% since January 2021. P&G chief financial officer, Andre Schulten, said his company might take a hit of one penny per share in the third quarter due to the war between Russia and Ukraine, while the impact may rise to four cents in the fourth quarter of 2022. Those remarks were related to the fact that P&G was ending its new capital investments in Russia and "significantly reducing" its portfolio to focus on basic hygiene, health, and personal care. The share of P&G's deliveries in Russia and Ukraine costs a little bit more than 1.5% of its global sales. 

Businesses which produce staples usually stand on firm ground during the time of severe inflation storms. They sell simple and necessary goods that people have gotten used to over the years. Housewives are unlikely to look for something and refuse to buy Pampers for their babies, for example, or to replace hygiene products like Tampax, Naturella, Always, the usual lines of Pantene, Wella and Head & Shoulders shampoos, Max Factor cosmetics or Fairy, Tide, Lenor, Comet and Mr Proper. If  their husbands use Gillette razors, they would most likely stand by that brand even if the retail price is raised , especially when other trademarks are also adding on extra charges also. Loyal customers of all these easily recognisable products are unlikely to change their behaviour just for the sake of some very small cost discounts which make other rival products cheaper because they have gotten use to taking care of their bodies in their preferred manner and are familiar with the ingredients used in these products.

2798
296

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors